Research & clinical trials
Dr. Mustafa Hammad serves as founder and CEO of the American Medical Institute (Stockbridge, Georgia, USA and Ramallah, Palestine), chair of the institutional review board at Global Research Holdings, and leads investigator-initiated work conducted in collaboration with Hammad Neurologic Center in Ramallah. He has been a Certified Principal Investigator (CPI) since 2016.
Active investigator-led programs (AMI & HNC)
- Characterization of leukocyte-poor highly concentrated platelet-rich plasma (open double-spin protocol) — American Medical Institute & Hammad Neurologic Center.
- Modified technique for reducing claustrophobia in cervical and brain MRI using lateral decubitus positioning (randomized controlled trial) — AMI & HNC.
- MRI efficacy and safety post bone marrow–derived stem cell therapy for ACL tear — AMI & HNC.
- Efficacy and safety of supraorbital, supratrochlear, auriculotemporal, and occipital nerve blocks with PRP in chronic migraine — prospective study — AMI & HNC.
- Efficacy and safety of magnesium L-threonate in prevention of chronic migraine — prospective study — AMI & HNC.
- Efficacy and safety of steroids versus PRP in epidural injections for lumbar disc disease — double-blinded study — AMI & HNC.
- Efficacy and adverse events of PRP medial meniscus and intra-articular injections for medial meniscus tears and osteoarthritis — AMI & HNC.
- Efficacy and safety of PRP spinoplasty in chronic lower back pain due to disc and facet pathology — AMI & HNC.
- MRI efficacy and safety post non-surgical spinal decompression therapy — prospective study — AMI & HNC.
Selected industry-sponsored trials (principal investigator)
- Tezepelumab in severe uncontrolled asthma (Phase 3) — AstraZeneca.
- Intravenous neridronic acid in complex regional pain syndrome — Syneos Health.
- Lemborexant in insomnia disorder — Eisai.
- Octagam 10% in dermatomyositis (ProDERM) — Octapharma.
- Dalvance utilization registry (DRIVE) — Allergan.
- Dalbavancin versus comparator in pediatric ABSSSI — Allergan.
- Lemborexant in adults 55+ with insomnia — Eisai.
- Pharmacogenomic test assessment in medication regimen — medical monitor role.
- Levomilnacipran ER in adolescent major depressive disorder — Allergan.
- ASCENT COPD (aclidinium cardiovascular safety) — AstraZeneca.
- Extensively hydrolyzed casein formula allergy study — CliniPace.
- Symbicort vs formoterol COPD exacerbation study.
- Fingolimod PASSAGE safety cohort — Novartis.
- Fingolimod TRANSITION from natalizumab — Novartis.
- Acute ankle sprain pain efficacy study.
- Renin inhibitor in type 2 diabetes with hypertension — Phase IIa.
Sub-investigator & early career highlights
- Modified stem cells (SB623) in chronic motor deficit from ischemic stroke — SanBio.
- Pediatric ADHD pharmacokinetic study.
- Pediatric/adolescent excessive sleepiness in OSA.
- Primary insomnia polysomnography studies.
- Elderly chronic insomnia long-term safety.
- Restless legs syndrome fixed-dose study.
- ALS sensory abnormalities — principal investigator (Emory / SUNY era).
- NBI-5788 (APL) in relapsing-remitting MS — Neuroscience Biosciences.
- Betaseron weekly IM post-Avonex MS trial — Berlex.
Research approach
- Translational design linking biomarkers, imaging, and functional outcomes.
- Rigorous safety monitoring and ethics/IRB alignment across geographies.
- Practical endpoints that inform day-to-day neurology, pain, and sleep practice.
- Openness to multicenter collaboration and sponsor feasibility dialogue.